Global X Genomics & Biotechnology ETF (NASDAQ:GNOM) Short Interest Up 30.2% in March

Global X Genomics & Biotechnology ETF (NASDAQ:GNOM) was the recipient of a significant increase in short interest in March. As of March 15th, there was short interest totalling 16,400 shares, an increase of 30.2% from the February 28th total of 12,600 shares. Approximately 0.3% of the shares of the stock are short sold. Based on an average daily volume of 77,600 shares, the short-interest ratio is presently 0.2 days.

Global X Genomics & Biotechnology ETF Price Performance

Shares of GNOM stock traded up $0.21 during trading hours on Wednesday, hitting $7.98. The stock had a trading volume of 117,141 shares, compared to its average volume of 62,261. The stock has a market capitalization of $51.71 million, a price-to-earnings ratio of -3.41 and a beta of 1.03. Global X Genomics & Biotechnology ETF has a one year low of $7.67 and a one year high of $11.88. The stock’s 50-day moving average price is $9.36 and its two-hundred day moving average price is $10.09.

Institutional Trading of Global X Genomics & Biotechnology ETF

Large investors have recently added to or reduced their stakes in the company. Raymond James Financial Inc. bought a new position in shares of Global X Genomics & Biotechnology ETF during the 4th quarter valued at approximately $2,974,000. Flow Traders U.S. LLC bought a new position in Global X Genomics & Biotechnology ETF during the third quarter valued at $936,000. Armis Advisers LLC bought a new position in Global X Genomics & Biotechnology ETF during the fourth quarter valued at $432,000. Strive Asset Management LLC purchased a new position in shares of Global X Genomics & Biotechnology ETF in the 4th quarter worth $409,000. Finally, Two Sigma Investments LP increased its holdings in shares of Global X Genomics & Biotechnology ETF by 74.5% in the 4th quarter. Two Sigma Investments LP now owns 85,500 shares of the company’s stock worth $830,000 after buying an additional 36,500 shares during the last quarter. Institutional investors own 56.95% of the company’s stock.

About Global X Genomics & Biotechnology ETF

Complete Genomics, Inc is a life sciences company that has developed and commercialized a deoxyribonucleic acid (DNA) sequencing platform. Its complete genomics analysis platform (CGA) Platform, combines its human genome sequencing technology with its advanced informatics and data management software and its end-to-end, outsourced service model to provide its customers with data that is ready to be used for genome-based research.